CYP2D6 genotype analysis of a Thai population: platform comparison-Reference-Cited by-同舟云学术

CYP2D6 genotype analysis of a Thai population: platform comparison

Published:2018-08-01 Issue:12 Volume:19 Page:947-960
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Chamnanphon Monpat¹²,Gaedigk Andrea³,Vanwong Natchaya⁴,Nuntamool Nopphadol⁵,Hongkaew Yaowaluck¹²,Puangpetch Apichaya¹²,Sukasem Chonlaphat¹²

Affiliation:

1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

2. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok 10400, Thailand

3. Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City and School of Medicine, University of Missouri – Kansas City, Kansas City, Missouri, MO 64108, USA

4. Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10332, Thailand

5. Department of Pharmaceutical Care, Faculty of Pharmacy, Payap University, Chiangmai 50000, Thailand

Abstract

The highly polymorphic CYP2D6 gene locus leads to a wide range of enzyme activity. Since there are limited data for Thai, the major aim was to investigate CYP2D6 genetic variation in a large Thai population (n = 920). CYP2D6 genotyping was performed using four different platforms. Genotype call rates of the Luminex xTAG® and AmpliChip CYP450 test were 96.5% and 87.4%, respectively. Based on Luminex xTAG® data, the most common alleles and genotypes were *1 0 (49.6%), *1 (24.6%), *2 (10.8%), *5 (6.7%), *41 (6.5%) and *1/*10 (23.9%), *10/*10 (21.5%), *2/*10 (9.4%), *5/*10 (6.9%), *10/*41 (5.7%), respectively. Challenges and limitations of the platforms evaluated are discussed. These data add to our knowledge regarding interethnic variability in CYP2D6 activity and contribute to improving drug therapy in the Thai.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2018-0075

Reference52 articles.

1. Pharmacogenomics and Individualized Drug Therapy

2. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

3. Importance of CYP2D6 genotype/activity testing and applications

4. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Follow-Up Study on the Thai Pharmacogenomics Database-1 (TPGxD-1): Validating CYP2D6 Allele Calls Using Contemporary Bioinformatics Tools;2024-06-18

2. A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data;Clinical and Translational Science;2024-06

3. Haplotype phasing of CYP2D6: an allelic ratio method using Agena MassARRAY data;Translational Psychiatry;2024-02-12

4. Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications;Frontiers in Pharmacology;2024-02-05

5. Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients;BMC Psychiatry;2024-01-10